How vulnerable are the EU institutions to undue corporate influence, and what gaps exist in EU lobbying and ethics rules?
As the dust has settled after the European Parliament elections last month, we're taking another look at the election debates in several member states where excessive corporate influence on EU decision-making and other concerns about the role of lobbying in Brussels became a major theme. We have previously reported on Austria and Denmark, but in Germany and Spain there were also big breakthroughs in the level of debate about these important problems.
As the management board of the European medicines agency votes today on its new clinical-trial data transparency policy, fresh concerns are being raised about how EMA handles revolving door cases.
The recent investigation into the European Commission's influential advisory groups announced by the European Ombudsman is very good news. This could provide the impetus to ensure that when the Commission comes to review the rules next year, it is the public interest rather than corporate interests that are at the heart of EU decision making.
We are a small team that works fully independently of funding from the EU,
governments, political parties and corporations.
Every single donation helps us fight the hold of Big Business over the EU.